A61K 47/55
The modifying agent being also a pharmacologically or therapeutically active agent, i.e.
Official title: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
A61K47/55 (The modifying agent being also a pharmacologically or therapeutically active agent, i.e.) appears on 1,381 US grants and 2,902 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,381
- Published applications
- 2,902
- Assignees
- 1,141
- Inventors
- 5,841
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 5 | 0 |
| 1999 | 10 | 0 |
| 2000 | 6 | 0 |
| 2001 | 8 | 2 |
| 2002 | 16 | 16 |
| 2003 | 12 | 32 |
| 2004 | 5 | 25 |
| 2005 | 8 | 41 |
| 2006 | 10 | 30 |
| 2007 | 13 | 51 |
| 2008 | 6 | 33 |
| 2009 | 19 | 47 |
| 2010 | 19 | 69 |
| 2011 | 27 | 75 |
| 2012 | 35 | 53 |
| 2013 | 44 | 82 |
| 2014 | 49 | 109 |
| 2015 | 57 | 96 |
| 2016 | 62 | 119 |
| 2017 | 78 | 125 |
| 2018 | 100 | 128 |
| 2019 | 83 | 145 |
| 2020 | 97 | 172 |
| 2021 | 92 | 175 |
| 2022 | 81 | 255 |
| 2023 | 95 | 262 |
| 2024 | 116 | 294 |
| 2025 | 114 | 265 |
| 2026 | 98 | 201 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Benzoheterocycle substituted tetrahydroisoquinoline compound6 Oct 2026US 12,752,011 B2Jiangxi Jemincare Group Co., Ltd
- EGFR degraders and associated methods of use6 Oct 2026US 12,752,012 B2BeOne Medicines | GmbH
- Composition for preventing, ameliorating, or treating gastritis or peptic ulcer comprising anthocyanin-negatively charged polysaccharide complex as active ingredient22 Sep 2026US 12,741,029 B2Jbklab Co., Ltd.
- Vanillin derivative compounds inducing selective degradation of PLK122 Sep 2026US 12,741,030 B2Uppthera, Inc.
- Glutarimide compound and use thereof22 Sep 2026US 12,741,031 B2Medshine Discovery Inc.
- A combination therapy for cancer treatment8 Oct 2026US 2026/0306633 A1Purdue Research Foundation
- Degrader for decomposing cmet protein, and pharmaceutical composition comprising same8 Oct 2026US 2026/0306639 A1Innocure Therapeutics, Inc.
- Technologies targeting cell states8 Oct 2026US 2026/0306640 A1Auron Therapeutics, Inc.
- Helicase degraders8 Oct 2026US 2026/0306641 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Stat degraders and uses thereof8 Oct 2026US 2026/0306642 A1Recludix Pharma, Inc.
Most cited
By later US patents
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Means to achieve sustained release of synergistic drugs by conjugation378US 6,051,576 AUniversity of Kentucky Research Foundation · 2000
- Method for enhancing transmembrane transport of exogenous molecules352US 5,416,016 APurdue Research Foundation · 1995
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Method for enhanced transmembrane transport of exogenous molecules302US 5,108,921 APurdue Research Foundation · 1992